Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics

International Journal of Antimicrobial Agents

Volumn 45, Issue 6, 2015, Pages 657-661

  Cusato, Jessica ^a   Allegra, Sarah ^a   De Nicolò, Amedeo ^a   Boglione, Lucio ^a   Fatiguso, Giovanna ^a   Abdi, Adnan Mohamed ^a   Cariti, Giuseppe ^a   Di Perri, Giovanni ^a   D'Avolio, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

ABCB1; AKR1; BCRP1; FokI; IL28B; SLC28A2

Indexed keywords

ABCB1 PROTEIN, HUMAN; ANTIVIRUS AGENT; CARRIER PROTEIN; CIF NUCLEOSIDE TRANSPORTER; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PROLINE;

ADULT; ANALOGS AND DERIVATIVES; CHEMISTRY; CYTOSOL; FEMALE; GENETICS; GENOTYPING TECHNIQUE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MIDDLE AGED; MONONUCLEAR CELL; PHARMACOGENETICS; PLASMA; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY;

ADULT; ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOSOL; FEMALE; GENOTYPING TECHNIQUES; HUMANS; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; P-GLYCOPROTEINS; PHARMACOGENETICS; PLASMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROLINE; REAL-TIME POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY;

EID: 84931291205     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.01.019     Document Type: Article

References (14)

1. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
2. L. Boglione, A. De Nicolo, J. Cusato, G. Cariti, G. Di Perri, and A. D'Avolio Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir J Viral Hepat 21 2014 260 263
3. US Food and Drug Administration (FDA), Center for Drug Evaluation and Research Application number: 202258Orig1s000. Boceprevir 2011 FDA Silver Spring, MD
4. A. Ghosal, Y. Yuan, W. Tong, A.D. Su, C. Gu, and S.K. Chowdhury, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor Drug Metab Dispos 39 2011 510 521
5. A. D'Avolio, A. De Nicolo, D. Agnesod, M. Simiele, A. Mohamed Abdi, and S. Dilly Penchala A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir J Pharm Biomed Anal 78-79 2013 217 223
6. M. Simiele, A. D'Avolio, L. Baietto, M. Siccardi, M. Sciandra, and S. Agati, et al. Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a Coulter counter to determine intracellular drug concentrations Antimicrob Agents Chemother 55 2011 2976 2978
7. L. Boglione, J. Cusato, A. De Nicolo, G. Cariti, S. Allegra, and V. Ghisetti, et al. Identification of naive HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms Antiviral Res 106 2014 105 110
8. A. D'Avolio, A. Ciancio, M. Siccardi, A. Smedile, M. Simiele, and J. Cusato, et al. Negative predictive value of IL28B, SLC28A2 and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment Ther Drug Monit 34 2012 722 728
9. A. D'Avolio, A. De Nicolo, J. Cusato, A. Ciancio, L. Boglione, and S. Strona, et al. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients Antiviral Res 100 2013 114 119
10. C.J. Matheny, M.W. Lamb, K.R. Brouwer, and G.M. Pollack Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation Pharmacotherapy 21 2001 778 796
11. 1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients Ann Oncol 20 2009 175 181
12. 1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients Br J Clin Pharmacol 66 2008 240 246
13. R.P. Owen, J.H. Gray, T.R. Taylor, E.J. Carlson, C.C. Huang, and M. Kawamoto, et al. Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2 Pharmacogenet Genomics 15 2005 83 90
14. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401